Intuitive Surgical is a medical instruments & supplies business based in the US. Intuitive Surgical shares (ISRG) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $527.61 – a decrease of 1.65% over the previous week. Intuitive Surgical employs 13,676 staff and has a trailing 12-month revenue of around $7.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $527.61 |
|---|---|
| 52-week range | $304.50 - $544.38 |
| 50-day moving average | $498.17 |
| 200-day moving average | $435.35 |
| Wall St. target price | $531.62 |
| PE ratio | 86.1859 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $6.24 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $537.8 from 2024-11-14
| 1 week (2024-11-08) | 0.25% |
|---|---|
| 1 month (2024-10-16) | 12.84% |
| 3 months (2024-08-16) | 12.28% |
| 6 months (2024-05-16) | 35.66% |
| 1 year (2023-11-16) | 76.94% |
|---|---|
| 2 years (2022-11-16) | 104.46% |
| 3 years (2021-11-16) | 48.93% |
| 5 years (2019-11-15) | 183.28% |
Valuing Intuitive Surgical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Intuitive Surgical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Intuitive Surgical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 86x. In other words, Intuitive Surgical shares trade at around 86x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Intuitive Surgical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.9799. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Intuitive Surgical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Intuitive Surgical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 billion.
The EBITDA is a measure of a Intuitive Surgical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $7.9 billion |
|---|---|
| Operating margin TTM | 28.33% |
| Gross profit TTM | $4.2 billion |
| Return on assets TTM | 7.95% |
| Return on equity TTM | 15.97% |
| Profit margin | 28.51% |
| Book value | $43.75 |
| Market Capitalization | $191.6 billion |
TTM: trailing 12 months
We're not expecting Intuitive Surgical to pay a dividend over the next 12 months.
Intuitive Surgical's shares were split on a 3:1 basis on 4 October 2021 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Intuitive Surgical shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Intuitive Surgical shares which in turn could have impacted Intuitive Surgical's share price.
Over the last 12 months, Intuitive Surgical's shares have ranged in value from as little as $304.5 up to $544.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intuitive Surgical's is 1.389. This would suggest that Intuitive Surgical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.